Regeneron Pharma (REGN) PT Raised to $761 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $927.89 --0%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 20 | New: 16
Join SI Premium – FREE
Baird analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $761.00 (from $742.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $855 at Morgan Stanley
- Regeneron Pharma (REGN) PT Raised to $1,100 at Guggenheim
- OmniVision Group (603501:CH) PT Lowered to RMB91.10 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
